Cargando…
Association of Dipeptidyl Peptidase-4 Inhibitors Use with Reduced Risk of Hepatocellular Carcinoma in Type 2 Diabetes Patients with Chronic HBV Infection
SIMPLE SUMMARY: Hepatocellular carcinoma (HCC) was the sixth most common cancer and the third leading cause of cancer death worldwide in 2020. Several studies have demonstrated that both chronic hepatitis B virus (HBV) infection and type 2 diabetes mellitus (T2DM) are important risk factors for HCC....
Autores principales: | Chen, Tzu-I, Lee, Fu-Jen, Hsu, Wan-Lun, Chen, Yong-Chen, Chen, Mingchih |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9954498/ https://www.ncbi.nlm.nih.gov/pubmed/36831491 http://dx.doi.org/10.3390/cancers15041148 |
Ejemplares similares
-
Dipeptidyl Peptidase 4 Inhibitors Reduce Hepatocellular Carcinoma by Activating Lymphocyte Chemotaxis in Mice
por: Nishina, Sohji, et al.
Publicado: (2018) -
New insights into the role of dipeptidyl peptidase 8 and dipeptidyl peptidase 9 and their inhibitors
por: Cui, Chenkai, et al.
Publicado: (2022) -
The Effects of Dipeptidyl Peptidase 4 Inhibitors on Renal Function in Patients with Type 2 Diabetes Mellitus
por: Hsu, Wan-Chia, et al.
Publicado: (2022) -
Dipeptidyl peptidase 4 inhibitors and their potential immune modulatory functions
por: Shao, Shiying, et al.
Publicado: (2020) -
Serum and Adipose Dipeptidyl Peptidase 4 in Cardiovascular Surgery Patients: Influence of Dipeptidyl Peptidase 4 Inhibitors
por: Shibasaki, Ikuko, et al.
Publicado: (2022)